Navrogen, Incorporated Press Releases

• Published on May 5, 2025 - 15:53 GMT

  

  Navrogen Announces Publication on the CA125-Refractory NAV-006 Ab Treatment of Immunosuppressed Follicular Lymphoma

  Navrogen Inc Announces Publication on the CA125-Refractory NAV-006 Antibody for the Treatment of Immunosuppressed Follicular Lymphoma CHEYNEY, PA, UNITED STATES, May 5, 2025 /⁨EINPresswire.com⁩/ -- Cheyney, PA, May, 5 2025 - Navrogen, Inc., a …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on March 26, 2025 - 16:32 GMT

  

  Navrogen Announces Publication and Presentation at the AACR Annual Meeting of a Novel Antibody Engineering Platform

  Navrogen Inc Announces Publication of a Novel Antibody Engineering Platform CHEYNEY, PA, UNITED STATES, March 26, 2025 /⁨EINPresswire.com⁩/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies for cancer, …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on March 27, 2023 - 13:15 GMT

  Navrogen and National Cancer Institute Establish Collaboration Study Impact Immunosuppressive Factor CA125 on Rituximab

  Navrogen and the National Cancer Institute Establish Collaboration to Study the Impact of Immunosuppressive Factor CA125 on Rituximab Effectiveness CHEYNEY, PA, UNITED STATES, March 27, 2023 /⁨EINPresswire.com⁩/ -- Cheyney, PA, March 27th, 2023 — Navrogen …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on July 1, 2021 - 14:00 GMT

  Navrogen Signs Commercial Evaluation License Agreement with The National Cancer Institute

  Navrogen Signs Commercial Evaluation License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for ImmunoSuppressed Cancers CHEYNEY, PENNSYLVANIA, UNITED STATES, July 1, 2021 /⁨EINPresswire.com⁩/ -- Navrogen, Inc., a …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on January 11, 2021 - 13:40 GMT

  Navrogen Establishes Research Collaboration with The National Cancer Institute to Test Mesothelin-Targeting Therapies

  CHEYNEY, PA, UNITED STATES, January 11, 2021 /⁨EINPresswire.com⁩/ -- Navrogen Establishes Research Collaboration with The National Cancer Institute to Test Mesothelin-Targeting Therapies for Cancers Affected by Humoral Immuno-Oncology Factors Navrogen, …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on September 29, 2020 - 12:53 GMT

  Navrogen Signs Commercial License Agreement with The National Cancer Institute to Develop Next-Generation Therapies

  CHEYNEY, PA, UNITED STATES, September 29, 2020 /⁨EINPresswire.com⁩/ -- Navrogen Signs Commercial License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immuno-suppressed Cancers Cheyney, PA, September 29, 2020 -- …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on September 14, 2020 - 13:08 GMT

  Navrogen Awarded National Cancer Institute Grant to Develop Next-Generation Rituximab With Enhanced Therapeutic Effects

  Navrogen Awarded a National Cancer Institute Grant to Develop Next-Generation Rituximab With Enhanced Therapeutic Effects in Immuno-suppressed Tumors CHEYNEY, PENNSYLVANIA, UNITED STATES, September 14, 2020 /⁨EINPresswire.com⁩/ -- Navrogen Awarded a …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...